The phase 1 trial for a new CAR T-cell therapy, led by research leader Rob Weinkove, has demonstrated a low rate of typical side effects associated with CAR T-cell treatments. Notably, no patients experienced severe cytokine release syndrome (CRS) or neurotoxicity, enabling the transition to outpatient management. This approach not only benefits patients but also alleviates hospital capacity pressures. The therapy, with its curative potential and cost-effectiveness, is poised for implementation at Te Whatu Ora Health New Zealand sites.
The ENABLE trial represents a national effort, with participants from across Aotearoa receiving travel support from Leukaemia & Blood Cancer New Zealand. Beyond developing a novel CAR T-cell therapy, the trial has spurred advancements in New Zealand's regulatory approval processes for such therapies and in managing their toxicities.
Acknowledgment was given to Wellington Hospital’s Clinical Trial Unit, the nursing teams on Ward 5 North and at Te Rerenga Ora Wellington Blood & Cancer Centre, as well as to all study participants and their families. Additionally, an interview featuring Professor Carl June, a pioneer of the therapy, Dr. Robert Weinkove, and trial participant Michele Leggott provided insights into the trial's progress.
